Background: Ovarian cancers account for approximately 27% of all female tumors, with non-epithelial ovarian cell carcinoma being rare at around 10% of overall ovarian cancer cases. The aim of this study is to recognize the prognostic factors Reporting survival outcome in the form of OAS, DFS, and PFS.Aim and Objective(s):Defining the lines of treatment have been uses and recognize the prognostic factors Reporting survival outcome OAS, PFS, and DFS.Patients and Methods: This study included 56 patients, were recruited in the period between January 2005 and December 2020 with the following criteria: Proven non-epithelial ovarian carcinoma, all stages, age greater than 18 years.Results: all 56 patients (100%) underwent surgery: 96.4% had upfront early debulking, and 3.6% had interval debulking post-neoadjuvant chemotherapy. Fertility Sparing Surgery was performed in 50%, optimal debulking in 41.4%. Surgical debulking left no residual disease in 78.6%; 12 patients had residual disease.Chemotherapy was administered to 55.4% of patients, with 67.7% receiving the BEP regimen and 9 patients receiving other regimens. Pathological responses in 12 patients with residual disease 75% achieved complete response. The median (OAS) was 66 months. The 5-year OAS rate was 94.6% for 53 patients. Median (PFS) was 66 months, with a 5-year PFS rate of 85.7% for 48 patients. Among 44 completely treated patients, (DFS) was 83 months, with a 5-year DFS rate of 93.2% for 41 patients.Conclusion: by univariate analysis; performance status, stage, type of surgery, and tumor residual after debulking surgery were significant prognostic factors for survival.
No takes yet. Share an insight, caveat, or question.
Abdelrahman et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: